New combo aims to outperform standard care in advanced colon cancer
NCT ID NCT06951503
First seen Mar 07, 2026 · Last updated May 12, 2026 · Updated 9 times
Summary
This phase 3 trial compares a new drug (AK112) plus chemotherapy against the standard treatment (bevacizumab plus chemotherapy) for people with metastatic colorectal cancer that hasn't been treated yet. About 560 adults aged 18-75 with good performance status are being recruited. The main goal is to see if the new combination delays cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuanzhou, Guangdong, China
Contact
-
The Sixth Hospital,Sun Yat-sen University
RECRUITINGGuanzhou, Guangdong, 510000, China
Contact
Conditions
Explore the condition pages connected to this study.